

# Recommended use of COVID-19 vaccines (as of 25<sup>th</sup> Jan 2022, 12.24pm)

Age	Comorbidities	Primary series*	Booster
<5 years	N/A	No vaccine available ( <i>trials ongoing; data expected 2022Q2</i> )	
5-11 years	Moderate to severe immunosuppression**	3 doses Pfizer pediatric dose <i>(NACI recommendation; BC update pending)</i>	None
	None/other	2 doses Pfizer pediatric dose	
12-17 years	Moderate to severe immunosuppression**	3 doses mRNA	None
	None/other	2 doses mRNA <i>(Pfizer preferred)</i>	
18+ years	Moderate to severe immunosuppression**	3 doses mRNA	1 dose mRNA after 6 months <i>(Pfizer preferred for 18-29 yrs)</i>
	None/other	2 doses mRNA <i>(Pfizer preferred for 18-29 yrs)</i>	


\*Ideal interval dose 1→dose 2 at least 8 weeks, minimum 21 days

Dose 2→dose 3 at least 28 days (longer better immune response after dose 3, balanced against risks of delaying 3<sup>rd</sup> dose depending on individual situation)

\*\*<http://www.bccdc.ca/resource-gallery/Documents/Guidelines%20and%20Forms/Guidelines%20and%20Manuals/Epid/CD%20Manual/Chapter%20%20-%20Imms/Part4/COVID-19-vaccine-eligibility.pdf>



# Vaccine effectiveness against symptomatic disease



# Vaccine effectiveness against hospitalization

UK

Dose	Interval after dose (weeks)	VE vs hospitalisation
1	4+	58% (37-72)
2	2 to 24	64% (54-71)
2	25+	44% (30-54)
3	2 to 4	92% (89-94)
3	5 to 9	88% (84-91)
3	10+	83% (78-87)

USA  
Delta

Encounter/Predominant variant period/Vaccination status	VE, %* (95% CI)
ED or UC encounters	
Delta predominant	
Unvaccinated (Ref) —	
Any mRNA vaccine	
2 doses (14–179 days earlier)	86 (85–87)
2 doses (≥180 days earlier)	76 (75–77)
3 doses	94 (93–94)

Hospitalizations	
Delta predominant	
Unvaccinated (Ref) —	
Any mRNA vaccine	
2 doses (14–179 days earlier)	90 (89–90)
2 doses (≥180 days earlier)	81 (80–82)
3 doses	94 (93–95)

[https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/1048395/technical-briefing-34-14-january-2022.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1048395/technical-briefing-34-14-january-2022.pdf)

<https://www.cdc.gov/mmwr/volumes/71/wr/pdfs/mm7104e3-H.pdf>

# Vaccine effectiveness against hospitalization

UK

Dose	Interval after dose (weeks)	VE vs hospitalisation
1	4+	58% (37-72)
2	2 to 24	64% (54-71)
2	25+	44% (30-54)
3	2 to 4	92% (89-94)
3	5 to 9	88% (84-91)
3	10+	83% (78-87)

USA  
Omicron

Encounter/Predominant variant period/Vaccination status	VE, %* (95% CI)
<b>ED or UC encounters</b>	
<b>Delta predominant</b>	
Unvaccinated (Ref)	—
<b>Any mRNA vaccine</b>	
2 doses (14–179 days earlier)	86 (85–87)
2 doses (≥180 days earlier)	76 (75–77)
3 doses	94 (93–94)
<b>Omicron predominant</b>	
Unvaccinated (Ref)	—
<b>Any mRNA vaccine</b>	
2 doses (14–179 days earlier)	52 (46–58)
2 doses (≥180 days earlier)	38 (32–43)
3 doses	82 (79–84)
<b>Hospitalizations</b>	
<b>Delta predominant</b>	
Unvaccinated (Ref)	—
<b>Any mRNA vaccine</b>	
2 doses (14–179 days earlier)	90 (89–90)
2 doses (≥180 days earlier)	81 (80–82)
3 doses	94 (93–95)
<b>Omicron predominant</b>	
Unvaccinated (Ref)	—
<b>Any mRNA vaccine</b>	
2 doses (14–179 days earlier)	81 (65–90)
2 doses (≥180 days earlier)	57 (39–70)
3 doses	90 (80–94)

[https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/1048395/technical-briefing-34-14-january-2022.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1048395/technical-briefing-34-14-january-2022.pdf)

<https://www.cdc.gov/mmwr/volumes/71/wr/pdfs/mm7104e3-H.pdf>